$665.47 Million in Sales Expected for Steris PLC (STE) This Quarter

Wall Street analysts expect Steris PLC (NYSE:STE) to report $665.47 million in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Steris’ earnings, with the highest sales estimate coming in at $669.90 million and the lowest estimate coming in at $661.50 million. Steris reported sales of $646.77 million in the same quarter last year, which indicates a positive year over year growth rate of 2.9%. The business is scheduled to report its next quarterly earnings results on Tuesday, February 6th.

On average, analysts expect that Steris will report full-year sales of $665.47 million for the current fiscal year, with estimates ranging from $2.60 billion to $2.62 billion. For the next fiscal year, analysts forecast that the business will post sales of $2.72 billion per share, with estimates ranging from $2.71 billion to $2.74 billion. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Steris.

Steris (NYSE:STE) last announced its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $0.94 EPS for the quarter, missing the consensus estimate of $0.95 by ($0.01). The firm had revenue of $634.20 million for the quarter, compared to analysts’ expectations of $629.02 million. Steris had a net margin of 5.59% and a return on equity of 11.49%. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.89 EPS.

Several equities analysts have recently issued reports on the company. Zacks Investment Research raised Steris from a “hold” rating to a “buy” rating and set a $101.00 price target for the company in a research report on Monday, October 9th. Raymond James Financial reaffirmed a “market perform” rating and issued a $100.00 price target on shares of Steris in a research report on Wednesday, January 3rd. KeyCorp reaffirmed a “buy” rating and issued a $91.00 price target on shares of Steris in a research report on Tuesday, October 17th. Finally, TD Securities lifted their price target on Steris from C$14.00 to C$16.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $79.50.

Steris (STE) traded up $0.53 on Monday, hitting $91.96. The stock had a trading volume of 269,000 shares, compared to its average volume of 362,262. The company has a current ratio of 2.80, a quick ratio of 2.18 and a debt-to-equity ratio of 0.48. The stock has a market cap of $7,821.42, a price-to-earnings ratio of 54.74 and a beta of 1.27. Steris has a 12-month low of $65.26 and a 12-month high of $93.71.

In related news, VP John Adam Zangerle sold 3,650 shares of Steris stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $88.00, for a total value of $321,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.55% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STE. Janus Henderson Group PLC lifted its position in shares of Steris by 1,972.4% during the 2nd quarter. Janus Henderson Group PLC now owns 7,679,507 shares of the medical equipment provider’s stock valued at $625,880,000 after buying an additional 7,308,950 shares in the last quarter. Vanguard Group Inc. grew its position in Steris by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 6,879,760 shares of the medical equipment provider’s stock valued at $560,700,000 after acquiring an additional 107,644 shares during the last quarter. FMR LLC grew its position in Steris by 33.1% in the 2nd quarter. FMR LLC now owns 3,454,533 shares of the medical equipment provider’s stock valued at $281,544,000 after acquiring an additional 859,228 shares during the last quarter. State Street Corp grew its position in Steris by 53.2% in the 2nd quarter. State Street Corp now owns 2,336,074 shares of the medical equipment provider’s stock valued at $190,392,000 after acquiring an additional 811,622 shares during the last quarter. Finally, Fisher Asset Management LLC grew its position in Steris by 3.0% in the 3rd quarter. Fisher Asset Management LLC now owns 1,539,157 shares of the medical equipment provider’s stock valued at $136,061,000 after acquiring an additional 45,191 shares during the last quarter. Institutional investors own 89.59% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/22/665-47-million-in-sales-expected-for-steris-plc-ste-this-quarter-2.html.

Steris Company Profile

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Get a free copy of the Zacks research report on Steris (STE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Steris (NYSE:STE)

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply